In a just published article in San Diego Biotechnology Connection, Cardium Therapeutics was highlighted for its work in developing Generx, a DNA-based angiogenic growth factor therapeutic for the potential treatment of patients with advanced coronary artery disease.
Generx is designed to stimulate the growth of blood vessels in the heart to enhance blood flow in patients with insufficient flow due to atherosclerotic plaque restricting the arteries that supply the heart. Because Generex is delivered to the heart using a one-time intracoronary administration from a standard cardiac infusion catheter, it provides an affordable alternative to costly and invasive surgical revascularization procedures, especially important for patients around the world who are not good candidates for surgery, or who cannot afford it.
The article talks about how many biotech companies have switched their focus away from heart disease to other more profitable areas, such as cancer. As a result, companies such as Cardium are seen as critical in the ongoing battle against heart disease, still the world’s number one killer. The article also points out that Cardium’s work is based upon important discoveries made at the University of California, San Diego, where researchers found that a particular gene is capable of stimulating dramatic growth of blood vessels in hearts with coronary artery blockages. It also points to studies indicating that heart patients with improved collateral circulation have a better chance of survival.
In the article, Chris Reinhard, Cardium Chairman and CEO, describes the passion of those in the company who are rapidly moving things forward: “Our decade-long journey is shared with a small team of passionate people who have a great deal of persistence and expertise and who all share in the same common goal of developing a novel therapeutic that could change the quality of lives of millions.”
Although the article states Reinhard’s belief that the market for Generx is larger outside of the U.S., he expects Cardium to return to the U.S. following successful registration of Generx in Russia and other international markets.
For the complete interview, visit http://bit.ly/MbcomQ
For additional information, visit www.CardiumTHX.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
